(Marketwire - July 31, 2008) - Basel, Switzerland, July 31, 2008 - Basilea Pharmaceutica Ltd. announces that Toctino® (alitretinoin), a new oral therapy for severe refractory Chronic Hand Eczema (CHE), was recommended for regulatory approval under the European decentralized procedure and will become the first authorized treatment for this chronic disabling disease.
